HC Wainwright Reiterates Buy Rating for Summit Therapeutics (NASDAQ:SMMT)
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $45.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 135.73% from the stock’s previous close. SMMT has been […]
More Stories
Bank of South Carolina Co. (BKSC) To Go Ex-Dividend on October 8th
Bank of South Carolina Co. (NASDAQ:BKSC – Get Free Report) announced a quarterly dividend on Thursday, September 26th, NASDAQ reports....
BNY Mellon High Yield Strategies Fund (NYSE:DHF) to Issue Monthly Dividend of $0.02
BNY Mellon High Yield Strategies Fund (NYSE:DHF – Get Free Report) announced a monthly dividend on Tuesday, September 24th, Wall...
Sabine Royalty Trust (NYSE:SBR) to Issue Monthly Dividend of $0.44
Sabine Royalty Trust (NYSE:SBR – Get Free Report) announced a monthly dividend on Friday, October 4th, Zacks reports. Shareholders of...
RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (OPP) To Go Ex-Dividend on December 13th
RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (NYSE:OPP – Get Free Report) declared a monthly dividend on Friday, October 4th, Wall Street...
Insider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Director Sells $10,313.31 in Stock
Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) Director William Richard White sold 201 shares of the business’s stock in...
CONMED (NYSE:CNMD) Issues Q3 2024 Earnings Guidance
CONMED (NYSE:CNMD – Get Free Report) issued an update on its third quarter 2024 earnings guidance on Friday morning. The...